New combo therapy offers hope for Drug-Resistant lung cancer
Disease control
Recruiting now
This study tests whether adding savolitinib to osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutated NSCLC) that has stopped responding to osimertinib. It focuses on patients with low levels of a genetic change called MET amplification. The goal is…
Phase: PHASE2 • Sponsor: Qingdao Central Hospital • Aim: Disease control
Last updated May 01, 2026 16:04 UTC